Scrip
New filings and stem cell deal hold out promise for MS
25 January 2010
Ian Schofield
Please Login to read the full article.
25 January 2010
Ian Schofield
The recent US and EU filings for Novartis' fingolimod and the announcement of a UK collaboration on stem cell research are welcome developments for multiple sclerosis patients and doctors awaiting potential new treatments for this intractable and distressing disease.
But let's not get our...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Novartis files oral MS drug fingolimod in US and EU
- Merck Serono's cladribine may become first oral MS drug after positive Phase III results
- Novartis reports positive data for second fingolimod Phase III study in MS - update
- No clear path forward for secondary-progressive MS, says BioMS
EVENTS
Today
Berlin, Germany
Today
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
